Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tailwind Biotech is a synthetic biology company that leverages artificial intelligence to design optimized synthetic DNA sequences for biomanufacturing. Founded in 2022 and based in Copenhagen, the company specializes in creating best-in-class promoters, terminators, and gene codon optimizations to maximize yields in strain development. Their technology aims to replace traditional trial-and-error methods with predictive modeling, significantly improving gene expression and reducing development costs for the pharmaceutical and industrial enzyme sectors. By focusing on the "three Cs"—connect, contextualize, and converse with clinical and genetic data—Tailwind Biotech provides tools that accelerate the transition of new therapies from the lab to the market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TailWind Solutions.